Erythroblasts as a parameter for mortality in critical ill patients supported with extacorporeal membrane oxygenation. A retrospective study

• Conditions: R57.0; J80; Cardiogenic shock; Adult respiratory distress syndrome

• Registration Number: DRKS00023626
• Lead Sponsor: Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-12-10
• Study Completion: 2021-01-05
• Results First Posted: 2023-08-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

All critical ill patients supported with ECMO for more than 48 hours were permitted.

Exclusion Criteria

Critical ill patients supported with ECMO for less than 48 hours were excluded.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of erythroblasts in blood samples of critical ill patients with ECMO as a parameter for mortality

Secondary Outcome Measures

Name	Time	Method
28 days mortality